BTIG Builds Out Equity Research Group with Biotechnology Analyst Robert C. Hazlett, III

NEW YORK–(BUSINESS WIRE)– BTIG,
LLC announced today that Robert C. Hazlett, III has
joined the firm’s Equity Research Group as a Managing Director. Based in
BTIG’s New York office, Mr. Hazlett will cover small and
mid-capitalization biotechnology companies within the Healthcare Equity
Research division.

“Robert’s biotechnology coverage provides another important dimension to
our Healthcare Equity Research team,” said Karen Blando, Director of
Research at BTIG. “Biotechnology is a notable area of focus for our
clients, and Robert’s expertise will add to our already strong
healthcare offering.”

Mr. Hazlett has nearly 20 years of experience conducting biotechnology
and pharmaceutical equity research. Prior to joining BTIG, he was a
Biotechnology Equity Research Analyst at Ladenburg Thalmann & Co.
Previously, Mr. Hazlett was a Senior Research Analyst at Roth Capital
Partners. He accumulated over a decade of experience in emerging,
specialty and large cap pharmaceuticals while at BMO Capital Markets,
Suntrust Robinson Humphrey, Lehman Brothers and UBS. In 2015, Mr.
Hazlett was recognized as a top stock picker in the biotechnology sector
by the Thomson Reuters’ StarMine Analyst Awards.

“As the latest addition to our Healthcare Equity Research team, Robert
will be an extraordinary resource for our clients,” said Scott
Kovalik, Co-Founder and Chief Executive Officer of BTIG. “With
Robert’s experience and insight, he will increase our visibility into
the biotechnology sector.”

About BTIG

BTIG is a global financial services firm specializing in institutional
trading, investment banking, research and related brokerage services.
With an extensive global footprint and more than 500 employees, BTIG,
LLC and its affiliates operate out of 14 cities in North America,
Europe, Asia and Australia. BTIG offers execution, expertise and
insights for equities, equity derivatives, ETFs, fixed income (futures,
commodities, foreign exchange, interest rates, credit, and convertible
and preferred securities). The firm’s core capabilities include global
sales, portfolio, electronic and outsource trading, transition
management, investment banking, prime brokerage, capital introduction,
corporate access, research and strategy, commission management and more.
Disclaimer: https://www.btig.com/Disclaimer.aspx

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161026005215/en/